ESMO 2024 Insights: 1L EV + Pembro in Cis-Ineligible la/mUC - 5-Year Follow-Up of Study EV-103 DE/A

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

This video is featured in the 2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: 1L EV + Pembro in Cis-Ineligible la/mUC - 5-Year Follow-Up of Study EV-103 DE/A

By 2024 ESMO Annual Meeting Insights Hub FEATURING Jonathan Rosenberg

44 views

October 10, 2024

Comments 0

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Feat. K. Hanna, J. Strauss

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma and Qual…

Feat. R. Alter, A. Rezazadeh

2024 ESMO Annual Meeting Insights Hub: GU Videos

New

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

251 views

3 weeks ago

ESMO 2024 Summary: Practice-Changing Trials for Patients With Locali…

2024 ESMO Annual Meeting Insights Hub

P. Grivas

245 views

2 months ago

ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la…

2024 ESMO Annual Meeting Insights Hub

E. Plimack

173 views

1 month ago

View All

APCCC 2026

Fri, Feb 27, 2026

RENALC-BLADDR-PROSCA 2024

BLADDR 2024 - Hybrid Global Forum on GU Oncology

Wed, Nov 27, 2024

See 1 other

RENALC-BLADDR-PROSCA 2024

PROSCA 2024 - Hybrid Global Forum on GU Oncology

Thu, Nov 28, 2024

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

2024 ASCO® Annual Meeting Insights Hub

E. Hamilton

1.4K views

5 months ago

ASCO® GU 2024 Summary: "Important Prostate Cancer Take-Home Messages"

Insights from 2024 ASCO® GU Annual Meeting

E. Efstathiou

2.6K views

9 months ago

Recent GU Developments and Their Clinical Implications

Insights from 2024 ASCO® GU Annual Meeting

T. Powles, B. Rini

1.5K views

8 months ago

Bladder Cancer Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

1.4K views

5 months ago

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

AdventHealth

G. Sonpavde

1.9K views

7 months ago

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

1.2K views

7 months ago

Surgical Management of High-Risk and Locally Advanced Prostate Cancer

Yale Cancer Center

I. Kim

431 views

1 month ago

Updates in the Treatment and Management of Bladder Cancer

Integrity CE

M. Galsky, B. Guercio

283 views

3 months ago

AUA Advanced Prostate Cancer Guidelines: 2023 Update

Robert Dreicer

1.3K views

11 months ago

Testosterone Suppression and Recovery in Patients With Advanced Pros…

Benjamin L. Maughan

661 views

5 months ago

ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mC…

2024 ESMO Annual Meeting Insights Hub

R. Dreicer

276 views

1 month ago

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

Total Health

M. Reimers

529 views

8 months ago

ASCO® 2024 Insights: "Evaluation of Persistence and Adherence for Or…

2024 ASCO® Annual Meeting Insights Hub

J. Hafron

643 views

5 months ago

ESMO 2024 Summary: Practice-Changing Trials for Patients With Locali…

2024 ESMO Annual Meeting Insights Hub

P. Grivas

245 views

2 months ago

New

Visible vs. Invisible Cancers - The Genomics and Natural History

Laurence Klotz

178 views

2 weeks ago

Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting …

Insights from 2023 ESMO Annual Meeting

G. Sonpavde

853 views

1 year ago

New

Enhanced Diagnostics in Prostate Cancer: PSA and Beyond in 2024

Penn Medicine Abramson Cancer Center

D. Lee

194 views

1 week ago

ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la…

2024 ESMO Annual Meeting Insights Hub

E. Plimack

173 views

1 month ago

Developmental Therapeutics Highlights From ASCO® 2024

2024 ASCO® Annual Meeting Insights Hub

G. Sonpavde

533 views

4 months ago

New

ESMO 2024 Summary: Developmental Therapeutics Highlights

2024 ESMO Annual Meeting Insights Hub

G. Sonpavde

251 views

3 weeks ago

AUTOPLAY

Login

Login

Join VuMedi

ESMO 2024 Insights: 1L EV + Pembro in Cis-Ineligible la/mUC - 5-Year Follow-Up of Study EV-103 DE/A

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Hypothetical Patient Case: 1L Advanced Renal Cell Carcinoma and Qual…

2024 ESMO Annual Meeting Insights Hub: GU Videos

ESMO 2024 Summary: Developmental Therapeutics Highlights

ESMO 2024 Summary: Practice-Changing Trials for Patients With Locali…

ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la…

Recommended

APCCC 2026

BLADDR 2024 - Hybrid Global Forum on GU Oncology

PROSCA 2024 - Hybrid Global Forum on GU Oncology

ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future Hold?"

ASCO® GU 2024 Summary: "Important Prostate Cancer Take-Home Messages"

Recent GU Developments and Their Clinical Implications

Bladder Cancer Highlights From ASCO® 2024

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Hyperprogression in Cancer Treated With Immunotherapy

Surgical Management of High-Risk and Locally Advanced Prostate Cancer

Updates in the Treatment and Management of Bladder Cancer

AUA Advanced Prostate Cancer Guidelines: 2023 Update

Testosterone Suppression and Recovery in Patients With Advanced Pros…

ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mC…

Best of Bladder Cancer and RCC From ESMO 2023 and GU ASCO 2024

ASCO® 2024 Insights: "Evaluation of Persistence and Adherence for Or…

ESMO 2024 Summary: Practice-Changing Trials for Patients With Locali…

Visible vs. Invisible Cancers - The Genomics and Natural History

Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting …

Enhanced Diagnostics in Prostate Cancer: PSA and Beyond in 2024

ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la…

Developmental Therapeutics Highlights From ASCO® 2024

ESMO 2024 Summary: Developmental Therapeutics Highlights